Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ROS1 G2032R
i
Other names:
ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6098
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(8)
News
Trials
Search handles
@DrJNaidoo
@JulienMazieres
@StephenVLiu
Search handles
@DrJNaidoo
@JulienMazieres
@StephenVLiu
Filter by
Latest
1year
Taletrectinib for ROS1 patients #ELCC23 : high response rates (52% in pretreated pts), prolonged PFS in both pretreated (12m) and naive (33 m) patients, robust intracranial activity, activity against G2032R, and tolerable safety with low incidence of neurological AEs. @OncoAlert (@JulienMazieres)
1 year ago
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 G2032R
|
taletrectinib (AB-106)
over1year
Report on #ROS1 TKI NVL-520 now @CD_AACR. Lack of TRK activity may improve safety profile. Very high preclinical potency for ROS1 G2032R and early clinical responses (including G2032R and CNS) reported here. #LCSM https://t.co/vMCOUeqxR2 (@StephenVLiu)
over 1 year ago
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 G2032R
|
zidesamtinib (NVL-520)
over1year
Update on #ROS1 NSCLC by Dr. @JessicaJLinMD at #DCLung22 including latest data on repotrectinib from #ENA2022. Promising activity with novel agents including against ROS1 G2032R especially NVL-520 with compelling (early) efficacy and safety data, first presented a few days ago! (@StephenVLiu)
over 1 year ago
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 G2032R
|
Augtyro (repotrectinib) • zidesamtinib (NVL-520)
2years
#TTLC22 Emerging #ROS1 agents highlighted by Dr. @alexdrilon. What's hot, what's not, and what might be hot? G2032R better met with repotrectinib and taletrectinib than lorlatinib. Already seeing these newer drugs in the first line space with great results! #LCSM (@StephenVLiu)
2 years ago
Clinical
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 G2032R
|
Lorbrena (lorlatinib) • Augtyro (repotrectinib) • taletrectinib (AB-106)
over2years
Expert review of ROS1-fusion+ nsclc by @DralexGva where he highlights the different options- crizotinib, ceritinib, entrectinib, lorlatinib, repotrectinib. Assessing for G2032R may help to guide choices #LCSM #LungSummit (@DrJNaidoo)
over 2 years ago
Review
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ROS1 fusion • ROS1 G2032R
|
Xalkori (crizotinib) • Rozlytrek (entrectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • Augtyro (repotrectinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login